






AREA OF THERAPY	PRECLINICAL	PHASE I	PHASE II	PHASE III	COMMERCIAL RIGHTS	
HEMATOLOGIC MALIGNANCIES						
Multiple Myeloma Relapsed/refractory BOSTON Penta-refractory STORM Relapsed/refractory STOMP			SELINEXOR + VELCADE ¹			
			SELINEXOR ²			
			SELINEXOR + BACKBONE THERAPIES ³			
Diffuse Large B-cell Lymphoma SADAL			SELINEXOR		 Japan*	
SOLID TUMOR MALIGNANCIES						
Liposarcoma SEAL			SELINEXOR			
Endometrial Cancer SIENDO ⁴			SELINEXOR		 China**	
Glioblastoma KING			SELINEXOR			
ADDITIONAL ONCOLOGY PROGRAMS						
MDS, CRC, PrC			ELTANEXOR (KPT-8602)		 China***	
Solid Tumors & Lymphoma			KPT-9274			
OTHER INDICATIONS						
Lymphoma in Companion Animals			VERDINEXOR (KPT-335)		 ANIVIVE**** LIFESCIENCES	

1 Oral selinexor, Velcade® (bortezomib) and dexamethasone vs. Velcade and dexamethasone

2 Oral selinexor + dexamethasone

3 Oral selinexor and dexamethasone + Revlimid® (lenalidomide), Pomalyst® (pomalidomide), Velcade, Kyprolis® (carfilzomib) or Darzalex® (daratumumab)

4 Investigator-sponsored randomized Phase III trial

*Ono licensed rights to selinexor and eltanexor in the following territories: Japan, S. Korea, Taiwan, Hong Kong, and ASEAN countries
 ** Antengene licensed rights to selinexor and eltanexor in China and Macau
 *** Antengene licensed rights to KPT-9274 and verdinexor in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries
 ****Anivive holds exclusive worldwide rights to research, develop and commercialize verdinexor only for the treatment of cancer in companion animals